Current trends of clinical trials involving CRISPR/Cas systems.

Publication date: Sep 11, 2023

The CRISPR/Cas9 system is a powerful genome editing tool that has made enormous impacts on next-generation molecular diagnostics and therapeutics, especially for genetic disorders that traditional therapies cannot cure. Currently, CRISPR-based gene editing is widely applied in basic, preclinical, and clinical studies. In this review, we attempt to identify trends in clinical studies involving CRISPR techniques to gain insights into the improvement and contribution of CRISPR/Cas technologies compared to traditional modified modalities. The review of clinical trials is focused on the applications of the CRISPR/Cas systems in the treatment of cancer, hematological, endocrine, and immune system diseases, as well as in diagnostics. The scientific basis underlined is analyzed. In addition, the challenges of CRISPR application in disease therapies and recent advances that expand and improve CRISPR applications in precision medicine are discussed.

Open Access PDF

Concepts Keywords
Cancer cancer
Genome clinical trials
Hematological COVID-19
Powerful CRISPR
Therapeutics gene therapy
genome editing


Type Source Name
disease MESH genetic disorders
disease VO gene
disease MESH cancer
disease MESH immune system diseases
disease MESH hemoglobinopathies
disease MESH COVID 19
pathway REACTOME Immune System
disease VO Bacteria
disease VO Archaea
disease VO Viruses
disease IDO host
disease IDO process
disease IDO site
disease MESH frame shift mutations
disease MESH premature stop codons
disease VO efficient
disease MESH meningitides
disease VO effective
drug DRUGBANK Adenine
disease VO efficiency
drug DRUGBANK Hypoxanthine
pathway KEGG Mismatch repair
drug DRUGBANK Penciclovir
drug DRUGBANK Zinc
disease MESH thalassemia
disease MESH HIV infection
disease MESH hematologic malignancies
disease IDO cell
disease MESH histocompatibility
disease MESH lymphoma
disease MESH lymphoblastic leukemia
disease MESH death
disease MESH immune tolerance
disease MESH non Hodgkin lymphoma
disease VO dose
disease IDO intervention
disease IDO country
disease VO Canada
disease MESH leukemia
disease MESH B cell leukemia
disease MESH B cell lymphoma
disease MESH multiple myeloma
drug DRUGBANK Cyclophosphamide
drug DRUGBANK Fludarabine
disease MESH syndrome
disease MESH opportunistic infections
disease MESH complications
disease MESH renal carcinoma
disease MESH T cell lymphoma
drug DRUGBANK Paclitaxel
disease MESH melanoma
pathway KEGG Melanoma
disease MESH gastrointestinal cancers
disease MESH Hematologic diseases
disease VO organization
disease MESH point mutations
disease MESH anemia
disease MESH thalassemia major
disease IDO blood
disease MESH iron overload
drug DRUGBANK Iron
disease VO IroN
drug DRUGBANK Isoxaflutole
disease VO protocol
drug DRUGBANK Tricyclazole
disease VO frequency
disease MESH pneumonia
disease MESH neutropenia
disease MESH sinusoidal obstruction syndrome
drug DRUGBANK Glutamic Acid
drug DRUGBANK L-Valine
drug DRUGBANK Sulodexide
disease MESH hemolysis
disease MESH sepsis
disease MESH cholelithiasis
disease VO company
disease IDO production
disease MESH Respiratory system diseases
disease IDO infectivity
disease MESH infection
disease VO time
drug DRUGBANK Gold
drug DRUGBANK Fluorescein
disease MESH pulmonary diseases
disease MESH diabetes mellitus
disease MESH autoimmunity
drug DRUGBANK Spinosad
disease IDO immunosuppression
disease VO device
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Oxygen
disease MESH familial hypercholesterolemia
disease MESH atherosclerosis
disease MESH heart attack
drug DRUGBANK Cholesterol
disease MESH hypercholesterolemia
disease VO monthly
disease MESH Hereditary transthyretin amyloidosis
disease MESH dissociation
disease MESH polyneuropathy
disease MESH cardiomyopathy
disease VO injection
pathway KEGG Endocytosis
drug DRUGBANK Vitamin A
disease MESH vitamin deficiency
disease MESH amyloidosis
disease MESH Acquired immunodeficiency syndrome
disease IDO immunodeficiency
disease IDO replication
disease VO titer
disease VO Lentivirus
disease MESH insertional mutagenesis
disease IDO virulence
disease VO effectiveness
drug DRUGBANK Ranitidine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Methyl isocyanate
disease MESH neurodegenerative diseases
drug DRUGBANK Cytidine
drug DRUGBANK Troleandomycin
drug DRUGBANK Methionine
drug DRUGBANK Activated charcoal
drug DRUGBANK Guanosine
drug DRUGBANK Cobalt
disease VO Pal
disease MESH small cell lung cancer
pathway KEGG Small cell lung cancer
disease VO report
disease IDO susceptibility
disease VO population
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Caffeine
drug DRUGBANK Carboxyamidotriazole
disease IDO assay
disease IDO pathogen
disease MESH cardiovascular disease
disease MESH hereditary amyloidosis
pathway KEGG Homologous recombination
disease MESH familial amyloid polyneuropathy

Original Article

(Visited 1 times, 1 visits today)